To improve tolerance and adherence for PI3K/AKT/mTOR inhibitors, oncology nurses should preemptively provide patients with tools like loperamide for diarrhea and non-drowsy antihistamines for rash, instructing them to use them at the very first sign of symptoms.

When managing drug-induced rash, recurrence is often caused by restarting therapy before the initial rash has completely resolved. Patients may be eager to resume treatment and minimize lingering symptoms, so clinicians must explicitly educate them on the need for full resolution to prevent a cycle of recurrence.

Broad-spectrum RAS-on inhibitors like daraxonrasib present skin toxicity as a dose-limiting side effect. However, this rash is clinically distinct from that caused by EGFR inhibitors. It is often manageable with brief treatment interruptions, frequently without requiring dose reductions, and patients tend to acclimate to it over time.

Although 22% of patients experienced severe (Grade 3) mucositis, the treatment discontinuation rate due to adverse events was only about 3%. This disparity highlights that the side effect, while serious, was effectively managed with proactive dose reductions, preventing it from being a treatment-limiting factor for most patients.

To manage the common rash associated with the AKT inhibitor capivasertib, clinicians should prescribe non-sedating antihistamines twice daily. Crucially, patients should begin taking the antihistamine the day *before* starting capivasertib and continue for at least four weeks. This preemptive approach significantly reduces the incidence and severity of the rash.

When using the AKT inhibitor capivasertib, preventing rash is more effective than treating it. A recommended strategy for physicians unfamiliar with the drug is to prescribe twice-daily non-drowsy antihistamines proactively for the first 6-8 weeks, as the rash is difficult to manage once it appears.

The side effect profile of capivasertib is front-loaded. Key toxicities like diarrhea and rash appear quickly, leading to the majority (63%) of drug discontinuations occurring within the first three months. This highlights a critical window for proactive management and patient education to improve adherence.

Data from the SOLAR-1 trial showed that adding prophylactic antihistamines for patients taking alpelisib cut the incidence of all-grade rash in half and reduced high-grade rash by 40%. This has become a standard practice for mitigating dermatologic toxicity with this class of drugs.

When a toxicity like rash occurs with EV+pembrolizumab—which could be caused by either drug—the recommended strategy is to stop both. After the rash improves, reintroduce the drug least suspected of causing it first. If the rash does not recur, it helps confirm the other agent was the culprit.